作者：
Annalisa,Trama [1]
;
Giuseppe,Badalamenti [2]
;
Giacomo Giulio,Baldi [3]
;
Antonella,Brunello [4]
;
Morena,Caira [5]
;
Nora,Drove [6]
;
Andrea,Marrari [7]
;
Emanuela,Palmerini [8]
;
Bruno,Vincenzi [9]
;
Angelo Paolo,Dei Tos [10]
;
Giovanni,Grignani [11]
作者单位：
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
[1]
Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
[2]
'Sandro Pitigliani' Department of Medical Oncology, Hospital of Prato, Prato, Italy.
[3]
Department of Clinical and Experimental Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
[4]
Eli Lilly and Company, Sesto Fiorentino, Italy.
[5]
Eli Lilly and Company, Kobe, Japan.
[6]
Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.
[7]
Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
[8]
University Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: B.Vincenzi@unicampus.it.
[9]
Department of Medicine, University of Padua School of Medicine, Padua, Italy.
[10]
Division of Medical Oncology Candiolo Cancer Institute - FPO, IRCCS, Strada Provinciale 142, 10060 Candiolo, Torino, Italy.
[11]
DOI
10.1016/j.canep.2019.02.012
PMID
30870746
发布时间
2020-01-20
换一批
换一批
